Using advanced artificial intelligence can give patients a personalized assessment of their risk for significant events, such as heart attack or death.
Deep learning does a better job in predicting which patients will experience major adverse cardiac events than the current standard imaging protocols used to make these determinations, according to new research.
In a poster presented during the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, researchers from Cedars-Sinai Medical Center in Los Angeles created a novel deep learning algorithm that can give patients a personalized assessment of their annualized risk for these types of events, such as heart attack of death.
For more SNMMI 2021 Annual Meeting coverage, click here.
“These findings show that artificial intelligence could be incorporated in standard clinical workstations to assist physicians in accurate and fast risk assessment of patients undergoing SPECT MPI scans,” said Ananya Singh, MS, a research software engineer in the Slomka Lab at Cedars-Sinai. “This work signifies the potential advantage of incorporating artificial intelligence techniques in standard imaging protocols to assist readers with risk stratification.”
Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL.
Credit: Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.
To build their deep learning network, the team pulled data from 20,401 patients included in the largest available multi-center SPECT dataset – REgistry of Fast myocardial perfusion Imaging in NExt generation SPECT (REFINE SPECT). All patients had undergone SPECT MPI. The team used their network to score each patient on their individual likelihood to have a major adverse cardiac event during the average follow-up period of 4.7 years.
According to their analysis, the network was able to pinpoint the areas of the heart that were associated with an elevated risk of these events and return a risk score in less than 1 second. They determined that the patients with the highest deep learning scores had a 9.7-percent annual major cardiac event rate – a 10.2-fold increased risk over patients with the lowest scores.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.